Metabolic Health in Primary Care — Dr. Saira Bano
CME · 1 Credit · Metabolic & Ethnicity CME Academy
Metabolic Health in Primary Care:
Why It Matters
Dr. Saira Bano — GP, Special Interest in Obesity & Metabolic Health
Key points from this lecture
Eight clinical insights from Dr. Bano’s lecture — distilled for immediate use in your consulting room.
How to earn your CME credit
Watch the full lecture above, read through the key points below, then complete the 5-question assessment at the end of this course. Pass with 80% or above to receive your certificate of completion worth 1 CME credit.
Metabolic diseases cluster — they share one biology
Obesity, prediabetes, hypertension, fatty liver and type 2 diabetes are not separate conditions. They are driven by the same upstream process: insulin resistance, chronic inflammation and sedentary lifestyle. The patient in front of you with three conditions has one metabolic problem.
“The patient in front of you with obesity, raised blood pressure, slightly deranged lipids — it’s not three problems. There’s actually one metabolic patient.”
The silent window is primary care’s greatest opportunity
Metabolic dysfunction runs silently for years — often a decade or more — before it surfaces as a cardiovascular event. By the time the patient presents to hospital, the window has closed. Primary care is uniquely positioned to act before complications develop.
“That silent window is exactly where primary care lives. It’s our window of opportunity before it ends up with complications.”
Insulin resistance is the central upstream driver
Insulin resistance connects impaired glucose handling, endothelial dysfunction, dyslipidaemia, hypertension and accelerated atherosclerosis. Not all fat is equal — visceral and ectopic fat carry the highest cardiometabolic risk. Don’t be reassured by a normal BMI alone.
“If there’s one pathophysiological idea to take away, it’s the central role of insulin resistance — the upstream node that connects almost everything.”
Obesity is a chronic relapsing disease — not a choice
WHO, NICE and every major international guideline now recognise obesity as a chronic, progressive, relapsing biological disease. Adipose tissue becomes an endocrine organ driving neurohormonal dysregulation. Weight regain after dieting is biology — not moral failure. Change how we counsel patients.
“When our patients come back two years later, heavier again — that’s biology doing what biology does. It’s not moral failure.”
Sleep is a metabolic variable — screen for OSA routinely
Sleep deprivation raises hunger hormones, worsens insulin sensitivity and drives weight gain. Obstructive sleep apnoea is extremely prevalent in obesity and commonly missed — patients say “I’m just tired.” Treating OSA can transform blood pressure control. Use the Epworth Sleepiness Scale for any patient with obesity.
“Sleep is the metabolic variable that primary care often forgets. Patients sleeping less than six hours are biologically nudged towards weight gain.”
Focus on dietary quality, not calorie counting
Ultra-processed foods are independently associated with obesity, T2DM and cardiovascular disease — even after adjusting for calories. A Mediterranean-style diet rich in fibre and minimally processed foods improves glycaemic control. In consultation, the message that sticks: mostly plants, mostly cooked at home.
“I tend not to prescribe specific gram targets. I really focus on quality — eating foods, mostly plants, mostly cooked at home.”
Resistance training is medicine — prescribe it
Skeletal muscle accounts for around 80% of glucose disposal in the body. Resistance training directly improves insulin sensitivity and is especially critical for patients on GLP-1 therapy to prevent muscle loss. Breaking up prolonged sitting every 30–60 minutes is one of the cheapest metabolic interventions available.
“Skeletal muscle is one of the largest glucose disposal organs in the body. Protecting muscle through resistance work is metabolically protective.”
GLP-1 therapy is a tool — lifestyle remains the foundation
Semaglutide and tirzepatide have demonstrated 15–21% weight reduction in randomised trials alongside meaningful improvements in blood pressure, lipids and cardiovascular outcomes. These are cardiometabolic disease-modifying therapies. Pharmacotherapy is not a replacement for lifestyle — it is a partnership. Plan the discontinuation conversation before starting.
“Pharmacotherapy is not replacement for lifestyle. Lifestyle is still number one. It’s a partnership. It’s a tool.”